Podcasts about PFS

Jun 23, 2026 – Global fintech expert Rich Turrin discusses the US government's ban on Anthropic's advanced AI models and its broader geopolitical impact. He explains how these restrictions disrupt global access, push international businesses...

Bravada Gold's new CEO, Dr. Paul West-Sells, tells Mining Stock Daily why his new position was too good an opportunity to pass up. West-Sells was the former head of Western Copper and Gold. Bravada's flagship Wind Mountain property is a past producing open-pit/heap-leach mining operation. Wind Mountain property is located in Nevada, and the project has a preliminary economic assessment from 2022. West-Sells said an updated PEA is due this year, and then the company will release a PFS.

Jun 22, 2026 – In this first installment of a two-part Lifetime Planning series, Senior Wealth Manager Brendan McMurtrie and Wealth Advisor Ryan Puplava reveal why the annual financial review is your most powerful planning tool...

Filmmakers at the 28th Provincetown International Film Festival talk to In Emmy Winner Charlotte Robinson host of OUTTAKE VOICES™ in the first audio montage of this two-part series. First we talked with visual conceptual artist Jay Critchley who created this year's PIFF trailer with production by Arvid Tomayko. Jay's performance work and environmental activism have traversed the globe performing in Argentina, Japan, England, Holland, Germany, Colombia and the United States. Jay's social art practice also includes running the Provincetown Community Compact which works with artists and sponsors the annual Provincetown Harbor Swim for Life & Paddler Flotilla a fundraiser that has raised millions for AIDS and women's health that's celebrating its 39th year on September 12th. Then we chatted with director Sam McConnell and Brock Yurich about their feature film “Test” which won PIFF Audience Award Best Narrative Feature and was written by Yurich who also stars as Eddie. The film is about a small-town Ohio bodybuilder (Brock Yurich) who clashes with his devout mother as he pursues his dreams under a renowned coach. We talked about their inspiration for making this film and their spin on our current issues.  Next we talked to director Fredgy Noël about her short film “Hail Maya” about a faithful Catholic undergraduate on her last night in the dorms who trades salvation for sin by diving headfirst into a tangle of lust, love and betrayal that confession can't absolve. Fredgy a graduate of the MFA Graduate Film program at New York University is the recipient of the Spike Lee Production Grant and the Sandra Ifraimova Production Fund. Her last short film New York Day Women premiered at the Tribeca Festival where Noël's work has screened twice. Currently she is working on her first feature film. Then we concluded this segment with director Fergus Campbell and producer Lola Lafia whose feature film “Sparks” was honored with a PIFF John Schlesinger Narrative Special Mention. “Sparks” is a beautifully strange and unexpectedly tender film about identity, friendship and the need to escape as a group of teenagers in Sparks, Nevada attempt time travel exploring an urban legend that a Nevada reservoir is a time portal.    The Provincetown Film Society, Inc. (PFS) is a non-profit year-round organization and home of the Provincetown International Film Festival. PIFF creates a unique international platform for the west and east coast entertainment industry to experience the diversity and community of Provincetown. PFS is also dedicated to showcasing the work of acclaimed and emerging directors, producers and actors.  For More Info… LISTEN: 600+ LGBTQ Chats @OUTTAKE VOICES

Episode OverviewFor the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Professor Charles Herbaux to unpack the data, debate the clinical implications, and ask the question that's on every hematologist's mind: is this enough to change practice?Background: Setting the Stage for TafasitamabBefore diving into frontMIND, the episode provides context on tafasitamab, a CD19-targeting monoclonal antibodyL-MIND (Phase 2 — relapsed/refractory DLBCL):81 patients with R/R DLBCLORR 58%, complete response rate 41%Established activity of tafasitamab + lenalidomide in the relapsed settinghttps://pubmed.ncbi.nlm.nih.gov/32511983/First-MIND (Phase 1b — frontline DLBCL, IPI 2–5):66 patients randomized: tafa-R-CHOP (n=33) vs. tafa-len-R-CHOP (n=33)ORR: 75.8% vs. 81.8%, respectivelySerious treatment-emergent adverse events: 42.4% vs. 51.5%Provided the signal (and the safety caution) to move to phase 3https://pubmed.ncbi.nlm.nih.gov/37369099/The frontMIND TrialDesign: Phase 3, double-blind, placebo-controlled randomized trialIntervention: R-CHOP + tafasitamab (12 mg/kg IV days 1, 8, 15 per cycle) + lenalidomide (25 mg/day, days 1–10 per cycle)Control: R-CHOP + placebosGCSF mandatory (given double-blind design); VTE prophylaxis (heparin or aspirin) mandatory given lenalidomideEnrollment: May 2021 – March 2023; 899 patients randomizedPrimary endpoint: Investigator-assessed progression-free survival (PFS)Patient Population:Age 18–80; DLBCL or high-grade B-cell lymphoma, IPI 3–5Median age: 65 years96% advanced stage; 54% bulky disease; 31% ECOG PS 2; 82% elevated LDH55% IPI 3 / aaIPI 2; 43% IPI 4–5 / aaIPI 38% double/triple hit — a high-risk subgroup included despite R-CHOP being the controlBroad histologic inclusion: transformed lymphoma, grade 3B FL, T-cell/histiocyte-rich LBCL, EBV+ DLBCL, ALK+ LBCL, HHV8+ DLBCL Note: On retrospective central review, ~7% of patients had a different histology (roughly half had FL grade 1–3A), underscoring the diagnostic challenges in DLBCL~40% received pre-phase steroids; 8% rituximab; 4% vincristine prior to cycle 1Key Efficacy Results(Primary analysis at median follow-up 35.2 months) | Endpoint | Tafa-Len-R-CHOP | R-CHOP | HR / p-value | 2-year PFS | 71.1% | 62.9% | HR 0.75, p=0.0194 | 3-year PFS | 67.3% | 60.7% | ~6.6% absolute difference | Overall Survival | — | — | HR 0.85, p=0.27 (immature)Points of Discussion:Absolute PFS benefit at 2 years: ~8.2%; at 3 years: ~6.6% — a modest but statistically significant improvementOS curves cross early, then separate slightly from ~18 months; data remain immatureEarly censoring observed: ~17% (intervention) and ~14% (control) censored by 9 months — raises questions about off-protocol therapySubgroup consistency: PFS benefit appeared consistent across prespecified subgroups; specific subgroups discussed in the episodeSafety Adverse Event | Tafa-Len-R-CHOP | R-CHOP | Fatal treatment-emergent AEs | 6% (26 pts) | 4% (17 pts) | Diarrhea (any grade) | 25% | 17% | Febrile neutropenia | 17% (incl. 1 death) | 13% | Grade ≥3 anemia | 24% | 17% | Grade ≥3 thrombocytopenia | 27% | 14%The addition of tafasitamab and lenalidomide to R-CHOP adds meaningful hematologic toxicity, particularly thrombocytopenia and anemia, as well as diarrhea and febrile neutropenia.Key Discussion Points from the EpisodeDid the early-phase L-MIND and First-MIND data justify bringing tafasitamab into the front-line setting, and was tafa-len-R-CHOP the right intervention arm to take forward?Is R-CHOP the appropriate control for a patient population that includes 8% double/triple hit lymphoma?What are the implications of using investigator-assessed PFS as the primary endpoint — and how critical is effective blinding to the integrity of that endpoint?How do we interpret the early OS curve crossing and currently non-significant OS benefit?Is the ~8% absolute PFS improvement at 2 years clinically meaningful enough to change practice — particularly given the added toxicity?How should we think about patient selection: who would you prioritize for tafa-len-R-CHOP over standard R-CHOP in clinical practice?What does frontMIND mean for the DLBCL treatment landscape alongside polatuzumab-R-CHP (POLARIX)?Resources & Further ReadingfrontMIND trial: Lenz et al. Lancet. https://pubmed.ncbi.nlm.nih.gov/42217458/POLARIX: Tilly H, et al. NEJM 2022About BloodCancerTalksBloodCancerTalks is a medical education podcast hosted by Raj, Ashwin, and Eddie, dedicated to the latest advances in hematologic malignancies. New episodes available wherever you listen to podcasts.Follow us on X/Twitter for episode updates and hematology/oncology content. 

Jun 19, 2026 – Robert Rapier joins Jim Puplava for a revealing discussion on the true state of global oil markets following the Middle East peace deal. They explore depleted reserves, Iran's newfound leverage, the challenges of restarting production...

Jun 19, 2026 – The shortest Fed statement in history just signaled a major shift—and Wall Street may not be ready. Jim Puplava and Macro Tides' Jim Welsh dig into Kevin Warsh's surprising break from forward guidance, why plunging oil...

Jun 19, 2026 – Could a second Great Depression hit by 2030? Financial Sense Newshour's Jim Puplava unpacks ITR Economics' sobering forecast—exploding national debt, surging interest costs, and unsustainable entitlements converging...

Jun 18, 2026 – Adriano Bosoni, RANE's Director of Geopolitical Analysis, discusses the US-Iran deal signed yesterday and the most likely scenario markets face over the next several months when it comes to the flow of traffic through the Strait...

In this Mining Stock Daily interview, Liberty Gold CEO Jon Gilligan breaks down Black Pine's growing oxide gold resource, now at 4.88 million indicated ounces, and the project's low-cost, high-leverage economics heading into a Q4 2026 Feasibility Study. He addresses the gap between the PFS base case and headline gold-price scenarios, the company's cost structure and capital needs, and what's left to prove before a 2028 construction decision.

Jun 16, 2026 – The Boock Report's Peter Boockvar discusses the AI capex boom, SpaceX's valuation, data center overbuilding risks, inflation volatility, Fed policy, and why oil, gold, silver, and commodities may still have room to run...

Jun 15, 2026 – Metabolic health expert Jim LaValle joins Jim Puplava to explain why being "disease free" doesn't mean you're truly healthy. They explore the overlooked drivers of premature aging, including chronic stress, poor sleep, and insulin resistance...

Jun 12, 2026 – Dave Keller, president and chief strategist at Sierra Alpha Research, offers a technical read on where equity markets actually stand regarding the largest IPO in history...

June 11, 2026 – In this week's Smart Macro, Jim Puplava is joined by Chief Investment Officer Chris Puplava for a hard look at what comes next for oil, inflation, and global markets during the second half of 2026...

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology 4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients) 5. PROTEUS - meh 6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly 7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC The Learning Oncology Companion from KelleyCPharmD: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Jun 10, 2026 – Gold just fell through its 200-day moving average, and Jordan Roy-Byrne says this is the second chance investors have been waiting for...

Will Robinson, VP of Exploration at West Red Lake Gold Mines (TSX.V:WRLG – OTCQB:WRLGF), joins me to review the key metrics returned from the updated Mineral Resource Estimate (MRE) at the Rowan Deposit and the first numbers from the Mt Jamie deposit.  Both Rowan and Mt Jamie are satellite deposits nearby the flagship Madsen Gold Project, in the Red Lake district of Ontario, Canada.  We also discuss some of the exploration news on tap in 2026 around the Madsen Mine.   HIGHLIGHTS:   Rowan Indicated gold ounces (“oz”) increased by 70% to 334,825 oz grading 13.03 grams per tonne gold (“g/t Au”), compared to 478,707 tonnes containing 196,747 oz grading 12.78 g/t Au in the 2025 MRE. Rowan Inferred gold oz increased by 52% to 179,013 oz grading 15.31 g/t Au, compared to 421,181 tonnes containing 118,155 oz grading 8.73 g/t Au in the 2025 MRE. Gold resource grade increased by 2% in the Indicated category and 75% in the Inferred category. Significant resource growth achieved with minimal exploration expenditures of C$3.5 million and relatively low drilling meters of 6,300m, representing a modest discovery cost of approximately C$17.60/oz gold. New drilling successfully expanded and upgraded several high-grade vein structures, including Veins 003, 006 and 013. Rowan continues to rank among the highest-grade undeveloped gold deposits in Canada based on an Indicated resource grade of 13.03 g/t Au. An initial resource estimate for the Mt. Jamie deposit was also prepared which includes an Indicated resource of 49,407 oz grading 14.13 g/t Au, with an additional Inferred resource of 35,791 oz grading 11.97 g/t Au. The Mt. Jamie deposit is located approximately 2km west of Rowan and shows strong potential for becoming an additional high-grade satellite in WRLG's Red Lake portfolio which presents obvious synergies to any future extraction scenario at Rowan. Expansion potential remains strong at Rowan and Mt. Jamie with mineralization open at depth and along strike and multiple vein zones demonstrating strong continuity beyond the currently modeled mineral domains.   ROWAN 2026 MINERAL RESOURCE ESTIMATE:   The 2026 MRE update for Rowan incorporates an additional thirty-seven (37) holes for 6,300m of oriented HQ diamond drill core since the June 2025 MRE. A total of twenty-two (22) mineral domains were created to constrain the Rowan mineralization. This is a reduction from the twenty-six (26) domains used in the June 2025 MRE. The M&I resources from Rowan will factor into the upcoming combined PFS with Madsen A total of five (5) mineral domains were created to constrain the Mt. Jamie mineralization using drilling data in the existing database.   Will mentions that more assays are still pending from the ongoing surface drilling into the prior-producing Starratt-Olsen area; which is near-surface and adjacent to the Fork deposit.   There will be upcoming underground drilling planned along Austin 904 Zone, South Austin 4447 Zone, and the 13 East Drive drifting over into Lower Austin and eventually Derlak.     If you have any follow up questions for the team over at West Red Lake Gold please email me at  Shad@kereport.com.   Click here to visit the West Red Lake Gold website and read over the recent news we discussed.   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine.The discussion focused on the following abstracts:·      Abstract 7512o   Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32).o   The progression-free survival (PFS) benefits observed in the trial support further evaluation of the quadruplet in a phase 3 study compared with other novel combination regimens in NDMM.·      Abstract 6505o   Revumenib (Revuforj) maintenance therapy after allogeneic stem cell transplantation showed feasibility in a heavily pretreated cohort of patients with acute myeloid leukemia (AML).o   Outcomes appeared favorable vs historical cohorts, supporting prospective assessment of maintenance menin inhibition among those with AML.·      Abstract 1503o   In a retrospective analysis of electronic medical records for 293 patients who received CAR T-cell therapy for lymphoma (n = 175), multiple myeloma (n = 106), or B-cell acute lymphoblastic leukemia (n = 12), outpatient monitoring was associated with significantly fewer hospital days without increased emergency department visits or 30-day mortality.o   These findings show the potential for lower healthcare utilization for patients who receive CAR T-cell therapy in the outpatient setting.·      Abstract LBA7000o   Adding tafasitamab (Monjuvi) and lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) significantly improved PFS vs R-CHOP alone among those with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the phase 3 frontMIND trial (NCT04824092).o   The data may support tafasitamab plus lenalidomide and R-CHOP as a potential new standard of care in the frontline treatment of patients with cell-of-origin subtypes of high-risk DLBCL.References Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: phase 1/2 BelaDRd study. J Clin Oncol. 2026;44(suppl 16):7512. doi:10.1200/JCO.2026.44.16_suppl.7512 Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505 Bowen SG, Abdallah N, Pritchett JC, et al. Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies. J Clin Oncol. 2026;44(suppl 16):1503. doi:10.1200/JCO.2026.44.16_suppl.1503 Lenz, G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000

Jun 5, 2026 – After a record-breaking rally, Gina Martin Adams, Chief Market Strategist at HB Wealth, joins Jim Puplava to discuss what's driving equities, risks from oil and inflation, the impact of hyperscaler investments, and her sector picks...

Jun 5, 2026 – Doomberg, head writer of the popular Substack, joins Financial Sense's Cris Sheridan to discuss oil market resilience, the real story behind U.S. emergency reserves, and why war escalation remains the only path to $150 oil...

Jun 4, 2026 – Kurt Kallaus at ExecSpec.net discusses what the prediction markets are pricing in for the Iran War and the Strait of Hormuz in addition to discussing his outlook for the US stock market and US economy in light of growing inflationary...

Jun 8, 2026 – Most people chasing wealth never plan for the one thing that makes it worth having: their health. In this episode of Lifetime Planning, Jim Puplava walks Cris Sheridan through his Super Longevity Protocol, a five-year project built inside his own wellness center...

Jun 5, 2026 – Financial Sense's Jim Puplava examines the emerging economic Cold War between the US and China, focusing on the competition for control over critical minerals, rare earths, and advanced technology. Jim explains how global...

Jun 3, 2026 –Woody Preucil discusses the accelerating race toward Q-Day, when quantum computers are expected to break encryption standards, posing major security and economic risks. He highlights rapid technological advances in China, urgent...

Jun 2, 2026 – Wall Street legend Ed Yardeni discusses why he's the most bullish strategist on the S&P 500, raising his 2024 target to 8,250. He explains the driving force behind this market rally, near-term risks from Fed actions and IPOs, and why...

Jun 1, 2026 – Explore the often-overlooked impact of state taxes on retirement strategies with Jim Puplava and Brendan McMurtrie. This episode dives into sophisticated approaches to Roth IRA conversions, highlighting the advantages and pitfalls...

May 29, 2026 – The market is feeding an AI mania, and consensus bulls are still looking higher. In this wide-ranging conversation, Jim Puplava interviews Samantha LaDuc, chief market strategist at LaDuc Trading, about what's really driving stocks into record territory...

May 29, 2026 – Dan Steffens says that we are facing an impending supply shock in the oil markets, with rapid global inventory drawdowns pointing to higher oil prices, rationing, and severe shortages—especially in Europe and Asia—as early as...

May 28, 2026 – Senior Bloomberg Intelligence agriculture analyst Alexis Maxwell discusses the sweeping impact of the ongoing Strait of Hormuz blockade on global fertilizer markets. She explains how it has disrupted key nutrients like nitrogen...

May 29, 2026 – Chief Investment Officer Chris Puplava joins Financial Sense to discuss the escalating risks in global oil markets amid ongoing geopolitical tensions and the depletion of strategic reserves. He cautions that current market optimism...

May 27, 2026 – FS Insider's Cris Sheridan and Tom Essaye discuss the AI data center and memory chip boom, surging tech capex, market impacts, and if this growth is sustainable. Key insights for investors following AI, tech trends, and valuations...

1022. If you were expecting interest rates to drop, rising inflation is making it more likely for them to go up this year. Laura reviews six moves you shouldn't overlook in a rising-rate environment to make your money work harder for you.Key takeawaysWhen inflation rises, the Fed raises interest rates to slow down spending and demand, eventually causing prices to decrease so spending increases.With sticky inflation and the expectation of rate hikes, borrowers need to watch interest rates on their debt, using a tool like my PFS.When variable-rate debts, such as credit cards, increase, it's wise to pay them off faster and reduce the interest expense.If you're considering a large purchase, like a home or vehicle, maintaining good credit and locking in a lower interest rate sooner rather than later are wise strategies.Higher interest rates benefit savers, so using a high-yield savings account can maximize your earnings.Discover more from Money Girl!FacebookNewsletterTranscripts available at QuickandDirtyTips.com.Email: Laura@LauraDAdams.com or leave a voicemail: (302) 364-0308. Hosted on Acast. See acast.com/privacy for more information.

May 26, 2026 – The Iran war highlights a new global era where the “peace dividend” of the post-Cold War period has given way to a costly “war tax” regime. Satyajit Das explains how soaring global defense spending, economic warfare tactics, and...

May 25, 2026 – Your Medicare premiums may be about to jump 20% or more, and most people are not prepared for it. In this eye-opening conversation, Jim Puplava sits down with Brian McArthur from Design My Medicare to unpack the forces driving the steepest supplement increases in years...

May 22, 2026 – Greg Weldon, publisher of the Global Macro Strategy Report, offers a candid assessment of current global economic risks. He discusses the geopolitical stalemate between the U.S. and Iran, highlighting the influence of China and Russia...

May 22, 2026 – Discover why microcontrollers—the tiny computers at the heart of today's smartest machines—are stealing the spotlight in tech and investing circles. In this interview, Financial Sense Wealth Management portfolio analyst...

May 22, 2026 – Just as Copernicus revolutionized astronomy, he also revealed the vital role of sound money. Ralph Benko explains how currency debasement endangers prosperity, and why Copernicus's age-old wisdom on stable money...

May 20, 2026 – We are living in an age of biblical miracles, but our ancient brains are failing to keep up. In this urgent conversation, Cris Sheridan interviews bestselling author Steven Kotler about his new book, We Are as Gods: A Survival Guide for the Age of Abundance ....

May 19, 2026 – FS Insider interviews John Butler at Amphora Report, former managing director at Deutsche Bank and Lehman Brothers, on the interplay between rising global bond yields, Middle East tensions, and soaring tech sector valuations...

In this episode, Dr. Rena Malik sits down with Dr. Irwin Goldstein to explore the complex effects of commonly prescribed medications—like SSRIs and finasteride—on sexual function. They break down the science behind persistent sexual side effects, new diagnostic ultrasound techniques, and the challenges patients face in navigating these risks. Listeners gain crucial insights into medication-induced sexual dysfunction and the importance of thoughtful, informed healthcare decisions. Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00 SSRIs and sexual dysfunction00:23: Irreversible neuronal changes01:13: Risks vs. benefits of SSRIs02:23: PSSD timing and presentation05:12: 5-alpha reductase inhibitors06:13: PFS and comparison to PSSD09:01: Penile fibrosis and ultrasound12:42: Erection hardness scale14:11: Viagra study and publication18:06: Sexual medicine gaps in gynecology Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Raj, Ashwin, and Eddie sit down with Dr. Vincent Rajkumar — Professor of Medicine at Mayo Clinic and Chair of the ECOG Myeloma Committee — for a clinically focused conversation on newly diagnosed multiple myeloma. Topics span baseline workup, risk stratification, induction selection, transplant timing, MRD-directed decision-making, and maintenance strategy. The episode closes with a discussion of Open Medicine, a new medical education platform, and Dr. Rajkumar's ongoing advocacy on drug pricing reform.KEY TOPICS DISCUSSEDBaseline workup: 24-hour urine protein: It is important to obtain 24-hour urine protein with electrophoresis and immunofixation in all newly diagnosed patients — not for diagnosis, but to establish a baseline for long-term management and to distinguish M-protein from albuminuria. In patients where an FLC ratio ≥100 is the sole myeloma-defining criterion, a 24-hour urine Bence Jones protein ≥200 mg is part of the diagnostic threshold for treatment initiation. Myeloma cast nephropathy: when to biopsy: An involved FLC ≥50 mg/dL supports a presumptive diagnosis of cast nephropathy and treatment can begin without a kidney biopsy. Below this threshold — particularly if renal involvement is the sole myeloma-defining event — kidney biopsy is warranted to exclude light chain deposition disease, MPGN, or other unrelated disorders. It warrants aggressive early treatment (Dara-VCD or Dara-VD), starting even before bone marrow results are available when the diagnosis is clinically clear.Solitary plasmacytoma [with or without minimal bone marrow involvement]: Patients with ~10% clonal plasma cells technically meet criteria for myeloma, but management in this borderline zone warrants shared decision-making. Solitary plasmacytoma as sitting between smoldering myeloma and overt myeloma on the disease spectrum. Risk stratification: revised IMWG criteria: The new revision aimed to keep the high-risk designation to ≤15–20% of patients. Del 17p alone confers high-risk status. TP53 mutation without del 17p is exceedingly rare and FISH alone captures the vast majority of cases. All other cytogenetic abnormalities (t(4;14), t(14;16), t(14;20), 1q gain, 1p deletion, biallelic 1p) require at least one co-occurring abnormality to define high risk. Elevated β2-microglobulin with normal renal function is retained as a proxy for high tumor burden. Emergent indications for treatment initiation: The three situations warranting urgent treatment are acute cast nephropathy (days matter for renal recovery), cord compression (surgery vs. radiation vs. systemic therapy determined by acuity), and hypercalcemia. Induction regimen selection: For fit, transplant-eligible patients, the preferred induction is a quadruplet — Dara-VRd or Isa-VRd — with dose adjustment as needed. Triplets (Dara-Rd or Isa-Rd) are reserved for those unable to tolerate a quadruplet even with dose reduction. Carfilzomib-based induction is not favored: head-to-head data show no benefit of KRd over VRd in NDMM, and the cost differential is substantial. Lenalidomide dosing: Starting dose should be individualized: 15 mg for patients over 75, those with small body habitus (

May 18, 2026 – Seventy percent of wealth transfers fail by the second generation. And a staggering 90 percent fail by the third. In this eye-opening conversation, Jim Puplava interviews lead advisor Brendan McMurtrie about why most...

May 15, 2026 – Jim Welsh at Macro Tides highlights that massive AI spending by tech giants is currently driving GDP growth and boosting the stock market, but this growth is highly concentrated in a few sectors, especially semiconductors, making the market...

May 15, 2026 – Why can't America make its own chips, medicines, or missiles without China? Financial Sense Newshour sits down with systems thinker Craig Tindale for a wide-ranging conversation on the cracks running through the global supply chain...

May 14, 2026 – S&P 500 hits new highs, but Chris Puplava warns of key divergences: 20% of consumer discretionary stocks at 52-week lows, financials down 7% YTD, and narrowing breadth. Global liquidity still supports the rally, but tactical caution...

May 13, 2026 – Silver is flying. Copper is hitting new record highs. Oil prices, as well, remain elevated. What's the outlook for commodities and will they continue to move higher? FS Insider interviews Jeffrey Christian of CPM Group for an in-depth...

May 12, 2026 – FS Insider interviews David Abramson, Chief US Strategist at Alpine Macro, on market dynamics amid geopolitical risks and rapid technological change. They explore analogies to the Roaring Twenties, including David's warning...

May 11, 2026 – Losing a spouse or loved one is an emotional and overwhelming experience, and many people are left uncertain about the practical steps that follow. Financial Sense's Jim Puplava outlines a detailed survivor checklist...

May 8, 2026 – Jim Puplava interviews energy expert and documentary producer Robert Bryce about the surging backlash against AI data centers across the US. Bryce describes an unprecedented wave of local rejections and protests, driven...

May 8, 2026 – Veteran market strategist Jeffrey Huge joins Jim Puplava to discuss today's record-breaking markets, with the S&P and NASDAQ at all-time highs—yet underlying risks lurk. Huge flags unprecedented valuations, excessive leverage, and...